TRANMEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRANMEP (TRANMEP).
Tianeptine is a selective serotonin reuptake enhancer (SSRE) and also modulates glutamatergic signaling via AMPA and NMDA receptors. It increases serotonin transport in presynaptic neurons and enhances neuroplasticity.
| Metabolism | Primarily hepatic via beta-oxidation and S-methylation; minor CYP450 involvement (CYP3A4, CYP2C19, CYP1A2). Main metabolite is MC5 and MC3. |
| Excretion | Renal: ~60% as unchanged drug, biliary/fecal: ~30% as metabolites, remainder as unchanged drug. |
| Half-life | 4-6 hours in adults; prolonged in hepatic impairment (up to 12 hours) and elderly. |
| Protein binding | ~95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1-2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 70-80% due to first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; IV: within 5 minutes. |
| Duration of Action | Oral: 4-6 hours; IV: 2-4 hours. |
50 mg orally every 8 hours, may increase to 100 mg every 8 hours if needed.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 50 mg every 12 hours. GFR 15-29 mL/min: 50 mg every 24 hours. GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 50 mg every 12 hours. Child-Pugh C: not recommended. |
| Pediatric use | 1-2 mg/kg orally every 8 hours, maximum 50 mg per dose. |
| Geriatric use | 50 mg orally every 12 hours; titrate cautiously due to increased risk of QT prolongation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRANMEP (TRANMEP).
| Breastfeeding | No data on excretion in breast milk. M/P ratio unknown. Due to long half-life and potential for accumulation, avoid use during breastfeeding or use with caution only if benefit outweighs risk. |
| Teratogenic Risk | Limited human data; animal studies not available. Based on pharmacologic similarity to tricyclic antidepressants, potential risk of neural tube defects if used in first trimester. Second/third trimester exposure may cause transient neonatal withdrawal or anticholinergic effects. Avoid if possible during organogenesis. |
■ FDA Black Box Warning
No FDA boxed warning exists as tianeptine is not approved by the FDA. However, abuse potential and withdrawal syndrome have been reported.
| Serious Effects |
Hypersensitivity to tianeptine, concurrent use with MAOIs (risk of serotonin syndrome), severe hepatic impairment, breastfeeding, history of substance abuse
| Precautions | Abuse potential (opioid-like effects at high doses), withdrawal syndrome (anxiety, insomnia, agitation), hepatotoxicity, serotonin syndrome (rare), lack of FDA approval in the US, risk of misuse/addiction, not recommended in children. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure and heart rate; fetal ultrasound for growth and anatomy if used in first trimester; neonatal monitoring for withdrawal symptoms (irritability, respiratory distress) if used near term. |
| Fertility Effects | No human studies. In animal models, at high doses, may cause disruption of estrous cycle and reduced fertility. Clinically, unlikely to cause significant fertility impairment at therapeutic doses. |